ArticleFrontiers in immunology2026
Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bulky tumor (T ≥ 50 mm) significantly compromises treatment outcomes in advanced non-small cell lung cancer (NSCLC) due to excessive tumor burden. Bronchial arterial chemoembolization (BACE) serves as an effective local intervention for reducing tumor size. The combination of immunotherapy and BACE has shown promising efficacy and an acceptable safety profile. However, the effectiveness of this combined regimen in patients with bulky tumors has not been thoroughly investigated. Methods: We conducted a retrospective analysis of 68 patients with advanced NSCLC (IIIB-IVB) who suffered from bulky tumors. Based on first-line treatment, patients were divided into two groups: those who received tislelizumab plus BACE followed by tislelizumab and systemic chemotherapy (Group A, n=34), and those who received tislelizumab plus chemotherapy alone (Group B, n=34). Outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Prognostic factors for PFS were identified using univariate and multivariate Cox regression analyses. Result: The ORR was significantly higher in Group A than in Group B (79.41% [27/34] vs 44.12% [15/34], Conclusion: In our cohort of patients with bulky tumors, this sequential strategy was associated with a favorable objective response rate and prolonged median progression-free survival, while maintaining a manageable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.